The impact of chronic bupropion on plasma cotinine and on the subjective effects of ad lib smoking: A randomized controlled trial in unmotivated smokers

Addictive Behaviors

Volumn 35, Issue 2, 2010, Pages 164-167

  Hussain, Sarwar ^a,b   Zawertailo, Laurie ^a,c   Busto, Usoa ^a,b   Zack, Martin ^a,c   Farvolden, Peter ^a,b   Selby, Peter ^a,c,d  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ONTARIO TOBACCO RESEARCH UNIT   (Canada)

Author keywords

Bupropion; Cue; Non treatment; Smoking; Subjective; Unmotivated

Indexed keywords

AMFEBUTAMONE; COTININE; PLACEBO;

ADULT; ARTICLE; BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MOTIVATION; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; SUSTAINED DRUG RELEASE; TREATMENT DURATION; WITHDRAWAL SYNDROME;

ADULT; BUPROPION; COTININE; CUES; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; SMOKING; TREATMENT OUTCOME;

EID: 70350761558     PISSN: 03064603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addbeh.2009.09.004     Document Type: Article

References (25)

1. Ahluwalia J.S., Harris K.J., Catley D., Okuyemi K.S., and Mayo M.S. Sustained-release bupropion for smoking cessation in African Americans: A randomized controlled trial. Journal of the American Medical Association 288 (2002) 468-474
2. Beck A.T., Steer R.A., and Garbin M.G. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clinical Psychology Review 8 (1988) 77-100
3. Brody A.L., Mandelkern M.A., London E.D., Childress A.R., Lee G.S., Bota R.G., et al. Brain metabolic changes during cigarette craving. Archives of General Psychiatry 59 (2002) 1162-1172
4. Brody A.L., Mandelkern M.A., Lee G., Smith E., Sadeghi M., Saxena S., et al. Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: A preliminary study. Psychiatry Research 130 (2004) 269-281
5. Cardenas L., Busto U.E., MacDonald A., and Corrigall W.A. Nicotine patches and the subjective effects of cigarette smoking: A pilot study. The Canadian Journal of Clinical Pharmacology 9 (2002) 175-182
6. David S.P., Strong D.R., Munafo M.R., Brown R.A., Lloyd-Richardson E.E., Wileyto P.E., et al. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: Analysis of pooled data from two clinical trials. Nicotine & Tobacco Research 9 (2007) 1251-1257
7. Durcan M.J., Deener G., White J., Johnston J.A., Gonzales D., Niaura R., et al. The effect of bupropion sustained-release on cigarette craving after smoking cessation. Clinical Therapeutics 24 (2002) 540-551
8. Fiore M.C., Jaen C.R., Baker T.B., Bailey W.C., Bennett G., Benowitz N.L., et al. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. American Journal of Preventive Medicine 35 (2008) 158-176
9. Heishman S.J., Saha S., and Singleton E.G. Imagery-induced tobacco craving: Duration and lack of assessment reactivity bias. Psychology of Addictive Behaviors 18 (2004) 284-288
10. Hesse L.M., Venkatakrishnan K., Court M.H., von Moltke L.L., Duan S.X., Shader R.I., et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants. Drug Metabolism and Disposition 28 (2000) 1176-1183
11. Hughes J.R., Stead L.F., and Lancaster T. Antidepressants for smoking cessation. Cochrane Database Systematic Reviews (2007) CD000031
12. Hurt R.D., Sachs D.P., Glover E.D., Offord K.P., Johnston J.A., Dale L.C., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. New England Journal of Medicine 337 (1997) 1195-1202
13. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine 340 (1999) 685-691
14. Lang P.J., Ohman A., and Vaitl D. The International Affective Picture System (photographic slides) (1998), Center for Research in Psychophysiology, University of Florida, Gainsville, FL
15. Lee A.M., Jepson C., Hoffmann E., Epstein L., Hawk L.W., Lerman C., et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biological Psychiatry 62 (2007) 635-641
16. Lerman C., Roth D., Kaufmann V., Audrain J., Hawk L., Liu A., et al. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug and Alcohol Dependence 67 (2002) 219-223
17. Levin E.D., Westman E.C., Stein R.M., Carnahan E., Sanchez M., Herman S., et al. Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. Journal of Clinical Psychopharmacology 14 (1994) 41-49
18. Rose J.E., Behm F.M., and Westman E.C. Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy. Experimental and Clinical Psychopharmacology 6 (1998) 331-343
19. Shiffman S., Johnston J.A., Khayrallah M., Elash C.A., Gwaltney C.J., Paty J.A., et al. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berlin) 148 (2000) 33-40
20. Siegel S. Drug anticipation and drug addiction. The 1998 H. David Archibald Lecture. Addiction 94 (1999) 1113-1124
21. Slemmer J.E., Martin B.R., and Damaj M.I. Bupropion is a nicotinic antagonist. Journal of Pharmacology and Experimental Therapeutics 295 (2000) 321-327
22. Tiffany S.T., and Drobes D.J. The development and initial validation of a questionnaire on smoking urges. British Journal of Addiction 86 (1991) 1467-1476
23. van Hanswijck de Jonge L., and Gormley M. Responses to positive and negative smoking-related images: Effects of current smoking status and degree of smoking addiction. Addictive Behaviors 30 (2005) 1587-1591
24. Watson D., Clark L.A., and Tellegen A. Development and validation of brief measures of positive and negative affect: The PANAS scales. Journal of Personality and Social Psychology 54 (1988) 1063-1070
25. Yamazaki H., Inoue K., Hashimoto M., and Shimada T. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Archives of Toxicology 73 (1999) 65-70